|
Novel Mechanisms of Beta-lactam Resistance in Staph Aureus, Continuation A120553 |
Henry Chambers, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Novel Mechanisms of Beta-lactam Resistance in Staph Aureus |
Henry Chambers, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Molecular Epidemiology and Geospatial Analysis of Tuberculosis Transmission in Uganda |
Gabriel Chamie, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine, Curry International Tuberculosis Center |
|
|
|
Sustainable approaches to care delivery in Uganda |
Gabriel Chamie, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Innovative incentive strategies for sustainable HIV testing and linkage to care |
Gabriel Chamie, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Leveraging social and sexual networks to reach young men with HIV testing and linkage services |
Gabriel Chamie, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
HIV Clinical Fellowship 2018 (Fellow May Baca) |
Susan Coffey, MD |
Division of HIV, ID and Global Medicine |
|
|
|
AETC National Coordinating Resource Center, Center for HIV Information UCSF S. Coffey |
Susan Coffey, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
HepC/HIV website |
Susan Coffey, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
HIVMA Clinical Fellowship Program (Baca) |
Susan Coffey, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Long Term Follow-Up of Patients Enrolled in Clinical Trials (#A-9602, A-9604, A-9801) Using Retroviral Gene Based Therapies / AIDS related research |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
GS-US-382-3961: A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
The Impact of Early Antiretroviral Therapy on HIV Persistence and Inflammation |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Characterizing the Role of Immune Activation in HIV Persistence |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Therapeutic vaccination and PD-1 blockade in treated HIV disease |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Identifying and targeting HIV persistence in T Cell subsets during ART |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Task Order: R24 for the CFAR-Network for the Integrated Clinical Sciences, CNICS |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Measuring the Latent reservoir for HIV |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Impact of interferon-alpha inhibition on immune function and viral persistence in HIV disease |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
T Regulatory Cells and T Cell Activation in HIV Disease |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
International Network for Strategic Initiatives in Global HIV Trials/ ICR INSIGHT |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Treating HIV-infected Elite Controllers as a Model of HIV Remission |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Treatment Intensification for Drug-Resistant HIV |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Enfuvirtide Treatment Intensification in Patients with Multi-Drug Resistant HIV |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Short-Term Disulfiram Administration to Reverse Latent HIV Infection |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
The Impact of Early Antiretroviral Therapy on HIV Persistence and Inflammation |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
HIV Controllers: A Potential Model for HIV Eradication |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Validation of Existing Ultra-Sensitive Assays for Quantifying HIV Persistence |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Identifying and Targeting HIV Persistence in T Cell Subsets during ART |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Innate Effector Function and HIV-1 Control |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Effects of CCR5 - delta-32 Heterozygosity on the HIV-1 Reservoir |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
HIV Entry Inhibitors: A New Therapeutic Option |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Master Agreement: International Network for Strategic Initiatives in Global HIV Trials/ICR INSIGHT |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Enhancing Control of HIV by Inhibiting TRAIL |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Atripla Adherence and Resistance Relationships [I] |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
HIV Specific T-Cell Responses in Rectal Mucosa |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Characterization of the HIV-1 Latent Reservoir in CCR5-Delta 32 Heterozygotes |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Disulfiram to Accelerate Decay in HIV Reservoirs in ART Treated Patients |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Viral control mechanisms of HIV-specific T cells in HIV-infected lymph node |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Elite Controllers |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
AIDS Clinical Trials Network (ACTG)-Deeks (Co-Vice Chair) A5296 |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Programming Long Term Durable HIV-1 Specific T cell Responses |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Atripla Adherence and Resistance Relationships [II] |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
HIV Persistence after Successful CCR5-Depleted Stem Cell Transplantation |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Enfuvirtide Intensification for Multi-Drug Resistant HIV |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Raltegravir Intensification in Antiretroviral-Treated Patients Exhibiting a Suboptimal CD4+T Cell Response |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Master Agreement: R24 for the CFAR-Network for the Integrated Clinical Sciences, CNICS |
Steven Deeks, MD |
Center for AIDS Research (CFAR), Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT): START |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
UCSF/Ragon Collaboration on HIV "Elite" Controllers |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Epigenetic Regulation of HIV Latency |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Combination immune checkpoint blocker inhibition to eliminate HIV latency |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Delaney AIDS Research Enterprise to Cure HIV |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Gender-specific Differences Affecting Reactivation of Latent HIV in Treated Patients |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Impact of HIV-Associated Inflammation on Disease |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Interruption of Enfuvirtide in Patients Experiencing an Incomplete Virologic Response to Enfuvirtide-Based Combination Antiretroviral Regimen |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Preventing the Establishment of Enfuvirtide-Resistance in the Latent Reservoir |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
San Francisco National Clinical Trial Center, ESPIRIT |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Impact of Sex-Based Differences on HIV Reservoir Size and Immune Activation |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Immediate Salvage Therapy w/ Combination ART plus T-20 vs. A 16 Week Structured Treatment Interruption Followed by Combination Therapy plus T-20 |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Core B: Specimen Repository Core |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Deeks Order CNICS: June 2014-Aug 2016 |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
EraMune Project |
Steven Deeks, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Impact of long-lasting insecticide treated bednets with and without PBO on malaria indicators in Uganda: a cluster randomised trial |
Grant Dorsey, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Program for Resistance, Immunology, Surveillance & Modeling of Malaria in Uganda (PRISM) Renewal |
Grant Dorsey, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Program for Resistance, Immunology, Surveillance & Modeling of Malaria in Uganda |
Grant Dorsey, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
PBO Study: Impact of LLINs with and without PBO in Uganda: a cluster-randomised trial - Innovative Vector Control Consortium (IVCC) |
Grant Dorsey, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Point-of-care Urine Monitoring of Adherence (PUMA): Testing a Real-Time Urine Assay of Tenofovir in PrEP |
Monica Gandhi, MD, MPH |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Plugging Hair ARV Levels as Adherence Biomarkers into HIV Prevention Trials |
Monica Gandhi, MD, MPH |
Division of HIV, ID and Global Medicine |
|
|
|
Novel Mass Spectrometry Imaging Methods to Quantify Antiretroviral Adherence |
Monica Gandhi, MD, MPH |
Division of HIV, ID and Global Medicine |
|
|
|
Developing a Mentoring Network of Diverse Mental Health Professionals Utilizing the CNICS Platform |
Monica Gandhi, MD, MPH |
Division of HIV, ID and Global Medicine |
|
|
|
Hair Extensions;: Using Hair Levels to Interpret Adherence, Effectiveness and Pharmacokinetics with Real-World Oral PrEP, the Vaginal Ring, and Injectables |
Monica Gandhi, MD, MPH |
Division of HIV, ID and Global Medicine |
|
|
|
HIV Clinical Fellowship |
Monica Gandhi, MD, MPH |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
AIDS Clinical Trials Group |
Monica Gandhi, MD, MPH |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Ryan White Title IV Women, Infants, Children, Youth and Affected Family Members AIDS Healthcare |
Monica Gandhi, MD, MPH |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Development of a point of care urine tenofovir immunoassay to distinguish adherence versus resistance-based HIV treatment failure |
Monica Gandhi, MD, MPH |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Measuring TB Drugs in Hair as a Tool to Monitor Adherence, Exposure and Response |
Monica Gandhi, MD, MPH |
Division of HIV, ID and Global Medicine |
|
|
|
Intervention to reduce drug use and HIV incidence among high PrEP priority partnered YMSM |
Monica Gandhi, MD, MPH |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Family Services Network - Ryan White HIV/AIDS Program |
Monica Gandhi, MD, MPH |
Division of HIV, ID and Global Medicine |
|
|
|
Expanded Multidisciplinary NeuroAIDS Research Training to Improve HIV Outcomes in Nigeria |
Monica Gandhi, MD, MPH |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Plugging Hair ARV Levels as Adherence Biomarkers into HIV Prevention Trials |
Monica Gandhi, MD, MPH |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Positive Health Access to Services and Treatment (PHAST) |
Monica Gandhi, MD, MPH |
Division of HIV, ID and Global Medicine |
|
|
|
Hair measures to assess adherence and explain outcomes in an HIV clinical trial |
Monica Gandhi, MD, MPH |
Division of HIV, ID and Global Medicine |
|
|
|
Assessing Antiretroviral Exposure in Diverse Populations |
Monica Gandhi, MD, MPH |
Division of HIV, ID and Global Medicine |
|
|
|
Adaptive Strategies for Preventing and Treating Lapses of Retention in Care (AdaPT-R) |
|
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Health Qual Impact Evaluation (HQIE) |
|
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Early Mortality in HIV-Infected Patients Starting Antiretroviral Therapy in Africa |
|
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
R24 for the CFAR-Network for the Integrated Clinical Sciences, CNICS |
|
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Differentiated care for improved health systems efficiency and health outcomes in Zambia (Efficient Health) |
|
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Geng Work Order CNICS: Crane R56 MI Packets |
|
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Quality Improvement Evaluation Center (Q-IEC) |
|
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Geng's work Order fee for Service Agreement / BMS MI A1424-562 |
|
Division of HIV, ID and Global Medicine |
|
|
|
Geng Work Order RTI Health Solutions (Services for RTI/ViiV) |
|
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
IeDEA Consortium East Africa data center |
|
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Work Order for CNICS Admin Core 5 Years (related to NIH R24 A1067039) |
|
IGHS Faculty Affiliate, Center for AIDS Research (CFAR), Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Better Information for Health in Zambia |
|
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Capacity Building and Strengthening Implementation of HIV Combination Prevention and Treatment Services |
|
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
R24 for the CFAR-Network for the Integrated Clinical Science, CNICS |
|
IGHS Faculty Affiliate, Center for AIDS Research (CFAR), Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
CFAR Network (CNICS) Research Platform: Channeling Bias Study |
|
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Mentoring Multidisciplinary Patient-Oriented Research in Engagement in HIV Care |
|
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Evaluation of Haiti Quality Improvement of HIV Care |
|
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Develop and host an open-access web-based database of implementation science research related to the HIV cascade of care |
|
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Evaluation of Haiti Quality Improvement of HIV Care |
|
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
P.falciparum infection dynamics and transmission to inform elimination (INDIE) |
Bryan Greenhouse, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
GenMoz P. falciparum genomic intelligence in Mozambique |
Bryan Greenhouse, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Modeling malaria incidence in Uganda using sentinel site surveillance data |
Bryan Greenhouse, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Phase 1 Train of Na-APR-w and Na-GST-1 Hookworm Vaccine in Brazilian Adults |
Bryan Greenhouse, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Mentoring translational scientists in international infectious disease research |
Bryan Greenhouse, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Malaria Serology evaluation |
Bryan Greenhouse, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
URBAN ARCH (3/5) Uganda Cohort - TB preventive therapy for HIV-infected alcohol users in Uganda: an evaluation of safety, tolerability, and adherence, Hahn U01 Renewal |
Judith Hahn, PhD, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Interventions to reduce alcohol use and increase adherence to TB preventive therapy among HIV/TB co-infected drinkers (DIPT 1/2) |
Judith Hahn, PhD, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Training in Research Program on Alcohol Use by Persons with our at Risk for HIV |
Judith Hahn, PhD, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Training in Research Program on Alcohol Use by Persons with our at Risk for HIV, Hahn K24 |
Judith Hahn, PhD, MD |
IGHS Faculty Affiliate, Department of Epidemiology and Biostatistics, Division of HIV, ID and Global Medicine |
|
|
|
Mobile technology to extend clinic-based counseling for HIV+s in Uganda |
Judith Hahn, PhD, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Development and Pilot Testing of a Combination Intervention to Reduce Heavy Drinking and Improve HIV Care Engagement among Fisherfolk in Uganda |
Judith Hahn, PhD, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Treating HIV-Infected Elite Controllers as a Model of HIV Remission |
|
Division of HIV, ID and Global Medicine |
|
|
|
Inflammatory and Clinical Consequences of Low-Level Viremia in HIV-1 Infected Patients |
|
Division of HIV, ID and Global Medicine |
|
|
|
Treatment to Reduce Inflammation and Improve Immune Recovery Among Older HIV Patients |
|
Division of HIV, ID and Global Medicine |
|
|
|
Virologic and Host Factors Contributing to HIV Control in Elite Controllers |
|
Division of HIV, ID and Global Medicine |
|
|
|
Feasibility of a Point-Of-Care CD4+ Test |
|
Division of HIV, ID and Global Medicine |
|
|
|
Treating HIV-Infected Elite Controllers as a Model of HIV Remission |
|
Division of HIV, ID and Global Medicine |
|
|
|
Administration of an ACE Inhibitor to Improve Endothelial Function in Treated, HIV-infected Individuals |
|
Division of HIV, ID and Global Medicine |
|
|
|
Administration of an ACE-Inhibitor to Decrease the Latent Reservoir |
|
Division of HIV, ID and Global Medicine |
|
|
|
ACE-Inhibitors to Decrease Lymphoid Fibrosis and the Size of the Latent Reservoir in Antiretroviral-Treated, HIV-infected Patients: A Randomized, Placebo-Controlled Study |
|
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Clinical Studies of Interactions Between HIV and Malaria |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Reducing Failure-to-Initiate ART: Streamlined ART Start Strategy (START) |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
SEARCH/AIDS Clinical Trial Research Group |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
HIV/TB in Uganda: Punctuated Antiretroviral Therapy |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG) |
Diane Havlir, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Adult AIDS Clinical Trials Unit (AACTU) |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
AIDS Clinical Trials Group; Protocol Funds |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
AIDS Clinical Trial Group (ACTG) Tuberculosis TSG Services |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
HIV/TB in Uganda: Punctuated Antiretroviral Therapy |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
UCSF HIV Clinical Trials Unit |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
ACTG A5335s Specialty Lab |
Diane Havlir, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
AIDS Research and Services at SF General Hospital |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Training in HIV Translational Research |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Clinical Care Response Team Introduction of Antiretroviral Therapy in Elizabeth Glaser Pediatric AIDS Foundation Sites |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Effect of Pitavastatin on Kidney Function in HIV-infected Persons |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
AIDS Clinical Trials Group: REPRIEVE Trial Ancillary Study |
Diane Havlir, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
SFBay CTU |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Novel Strategies to Prevent Malaria and Improve HIV Outcomes in Africa (III) |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
AIDS Clinical Trials Group (ACTG) TTSG Services |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Getting to Zero Coordinator/ SFPHF |
Diane Havlir, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Novel Strategies to Prevent Malaria and Improve Maternal-Child Health in Africa |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Study of Three NNNRTI-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (ACTG A5257) |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Sustainable East Africa Research in Community Health (SEARCH) |
Diane Havlir, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Therapeutic Strategies for HIV Disease |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
SEARCH (Sustained East Africa Research in Community Health) Study in Kenya and Uganda/ Gates |
Diane Havlir, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Cardiovascular, Anthropometric, and Skeletal Effects of ART Initiation with FTC/TDF plus ATV/r: Metabolic Substudy of A5257 (ACTG A5260s) |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Strategic antiretroviral therapy and HIV testing for youth in rural Africa (SATURN) |
Diane Havlir, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Sustainable East Africa Research in Community Health |
Diane Havlir, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
ACTG, AIDS Clinical Trial Research Group |
Diane Havlir, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Simplified Isoniazid Preventive Therapy (SPIRIT) Strategy to Reduce TB Burden |
Diane Havlir, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Trial of Raltegravir Plus Darunavir/Ritonavir for Treatment-Naive HIV-1-Infected Subjects (ATCG A5262) |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
AIDS Clinical Trial Research Group (ACTG), Studies: A5306, A5254, A5298 |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Training in HIV Translational Research |
Diane Havlir, MD |
IGHS Faculty Affiliate, Center for AIDS Research (CFAR), Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
ACTG A5295: Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in HIV-Infected and Uninfected Pulmonary Tuberculosis Suspects |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Therapeutic Strategies for HIV Disease |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Task Order # 7: Supplement to SSS A5254 |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
AIDS Clinical Trials Group (ACTG) Community Health Promoter |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Novel Strategies to Prevent Malaria and Improve Maternal-Child Health in Africa (PROMOTE) |
Diane Havlir, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
ACTG A5295: Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in HIV-Infected and HIV-Uninfected Pulmonary Tuberculosis Suspects |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
ADS-TCAD-P0206: TCAD Oral for Treatment of Influenza A |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Task Order # 9: Supplement to SSS A5272 |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Task Order A5303: Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naive Patients Infected with R5-Tropic HIV-1 |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
AIDS Clinical Trial Group Network- Protocol Funding Agreement (Core Funding) |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Supplement to ATCG A5254: Assessing HIV-Related Oral Mucosal Disease and Using Saliva to Measure Viral Load |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
UCSF HIV/AIDS Management Training Programs |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
International AIDS Research and Prevention |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Novel Strategies to Prevent Malaria and Improve HIV Outcomes in Africa (I) |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
TO#5 ACTG-Clinical Research Site - Community Health Promoter Position |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Training in HIV Translational Research |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Task Order A5280: A Prospective, Randomized Pilot Trial of High Dose Vitamin D and Calcium for Bone Health in HIV-Infected Individuals Initiating Highly Active Antiretroviral Therapy (HAART) |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Effect of low dose methotrexate on endothelial function and inflammation in HIV - A5314 |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Reducing Failure-to-Initiate ART: Streamlined ART Start |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Clinical Care Response Team Introduction of Antiretroviral Therapy in Elizabeth Glaser Pediatric AIDS Foundation Sites |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Neurological AIDS Research Consortium |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
AIDS Clinical Trials Group: REPRIEVE Trial (A5332 and A5333s) |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Training in HIV Primary Care - Uganda Clinicians |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Novel Strategies to Prevent Malaria and Improve HIV Outcomes in Uganda (II) |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Task Order # 6: Supplement to SSS A5257 |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Task Order Agreement No. CRB-DCR01-S-09-00325 |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Task Order Supplement to A5267 |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Productive and Latent HIV Infection in Gut Mucosal Reservoirs |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Heals Endowment Fund at the East Bay Community Foundation |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
AIDS Research and Services at SFGH |
Diane Havlir, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Specimens Related to the MU-UCSF Research Collaboration |
Laurence Huang, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Longitudinal Evaluation of HIV-associated Lung Disease Phenotypes |
Laurence Huang, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Transcriptional alternations in bronchoalveolar lavage fluid during treatment of human tuberculosis |
Laurence Huang, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Lung Microbiome in Cohorts of HIV-Infected Persons (Lung MicroCHIP) Study |
Laurence Huang, MD |
Division of HIV, ID and Global Medicine |
|
|
|
International HIV-Associated Opportunistic Pneumonias (IHOP) Study |
Laurence Huang, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Statins for Pulmonary and Cardiac Complications of Chronic HIV (The SPARC Trial) |
Laurence Huang, MD |
Division of HIV, ID and Global Medicine |
|
|
|
International HIV-Associated Opportunistic Pneumonias (IHOP) Study |
Laurence Huang, MD |
Division of HIV, ID and Global Medicine |
|
|
|
FIND Xpert MTB assay collaboration at Mulago Hospital |
Laurence Huang, MD |
Division of HIV, ID and Global Medicine |
|
|
|
HIV and Lung Complications in the HAART Era: Focus on Obstructive Lung Disease (ll) |
Laurence Huang, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Molecular Epidemiology of Human P. Carinii Pneumonia |
Laurence Huang, MD |
Division of HIV, ID and Global Medicine |
|
|
|
International Randomized, Controlled Phase 3 Trial of DB289 Versus Trimethoprim-Sulfamethoxazole for Treatment of Acute Pneumocystis jiroveci Pneumnia (PCP) in Patients with HIV/AIDS |
Laurence Huang, MD |
Division of HIV, ID and Global Medicine |
|
|
|
HIV and Lung Complications in the HAART Era: Focus on Obstructive Lung Disease(l)) |
Laurence Huang, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Pathogenesis of Emphysema/Obstruction and the Microbiome (POEM) in HIV |
Laurence Huang, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Patient-Oriented Research and Mentoring in Pneumocystis |
Laurence Huang, MD |
Division of HIV, ID and Global Medicine |
|
|
|
HIV and Lung Complications in the ART Era: Focus on Obstructive Lung Disease |
Laurence Huang, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Evaluate Serum-Based Assay for Pneumocystis Pneumonia Diagnosis |
Laurence Huang, MD |
Division of HIV, ID and Global Medicine |
|
|
|
PCP OPW Specimens |
Laurence Huang, MD |
Division of HIV, ID and Global Medicine |
|
|
|
PCP OPW Specimens/Uganda Project Support |
Laurence Huang, MD |
Division of HIV, ID and Global Medicine |
|
|
|
UCSF-FIND Uganda Project |
Laurence Huang, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Genotypic and functional properties of HIV-1 Nef clinical isolates in PAH-HIV |
Laurence Huang, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Transcriptional alterations in bronchoalveolar lavage fluid during treatment of human tuberculosis. |
Laurence Huang, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Patient-Oriented Research and Mentoring in HIV-associated Pulmonary Diseases |
Laurence Huang, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Inflammation, Aging, Microbes, and Obstructive Lung Disease (I AM OLD) Study |
Laurence Huang, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Cardiovascular, Pulmonary & Hematological Disease in HIV: Prevention & Treatment |
Peter Hunt, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Cardiovascular, Pulmonary & Hematological Disease in HIV: Prevention & Treatment |
Peter Hunt, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Innate Immune Response Genetics and T cell Activation in Treated HIV Infection |
Peter Hunt, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Mesalamine to Reduce T Cell Activation in HIV Infection |
Peter Hunt, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Investigating Mechanisms of HIV Persistence in the Gut |
Peter Hunt, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Determinants of Functional Immune Defects in Treated HIV Infection and Aging |
Peter Hunt, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
AIDS Clinical Trials Network (ACTG)- Peter Hunt Task Order |
Peter Hunt, MD |
Division of HIV, ID and Global Medicine |
|
|
|
AIDS Clinical Trials Network (ACTG) -- Peter Hunt Task Order |
Peter Hunt, MD |
Division of HIV, ID and Global Medicine |
|
|
|
IDO-induced Tryptophan Catabolism and Mortality in Treated HIV-infected Africans |
Peter Hunt, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Valganciclovir to Reduce T Cell Activation in HIV Infection |
Peter Hunt, MD |
Division of HIV, ID and Global Medicine |
|
|
|
HIV-Specific T-Cell Responses in Rectal Mucosa |
Peter Hunt, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Intestinal MAIT Cells in HIV Infection |
Peter Hunt, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
The Determinants of T Cell Activation in HIV Infection |
Peter Hunt, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Inflammation, T Cell Senescence, and Mortality in Treated HIV Infection |
Peter Hunt, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Novel approaches to monitoring and utilizing adherence to HIV therapy in Africa |
Peter Hunt, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Immunologic Determinants of CD4+ T Cell Recovery in Treated HIV+ Africans |
Peter Hunt, MD |
Division of HIV, ID and Global Medicine |
|
|
|
HIV-Specific T-cell Responses in Rectal Mucosa |
Peter Hunt, MD |
Division of HIV, ID and Global Medicine |
|
|
|
HIV Pathogenesis and Immunity in Viremic Non-Progressors |
Peter Hunt, MD |
Division of HIV, ID and Global Medicine |
|
|
|
AIDS Clinical Trials Network (ACTG) - Transformative Science Group Vice Chair) |
Peter Hunt, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Impact of Parasitemia on the Development of Cellular Immune Responses to Malaria |
|
Division of HIV, ID and Global Medicine |
|
|
|
Immunologic Consequences of Highly Effective Antimalarial Chemoprevention |
|
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Early Antiretroviral Therapy in Resource Limited Settings in Patients with High CD4+ Cell Counts |
Vivek Jain, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Early Antiretroviral Therapy in Resource Limited Settings in Patients with High CD4+ Cell Counts |
Vivek Jain, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Implementation science research on ART delivery in resource limited settings |
Vivek Jain, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
RAPID-VL: Optimizing HIV Viral Load Monitoring and Outcomes for High-Risk Populations |
Vivek Jain, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
HIV Emergence of Drug Resistance |
|
Division of HIV, ID and Global Medicine |
|
|
|
Adherence Improvement & Measurement (AIM) System |
|
Division of HIV, ID and Global Medicine |
|
|
|
Tibotec TMC125-C214: Early Access of TMC125 in Combination with Other Antiretrovirals in Treatment-Experienced HIV-1 Infected Subjects with Limited Treatment 0ptions |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Evaluation of doxycycline post-exposure prophylaxis to reduce sexually transmitted infections in PrEP users and HIV-infected men who have sex with men |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
ACTG, AIDS Clinical Trials Research Group - A5289 and A5255 |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Study Evaluating the Efficacy and Safety of Pegylated Interferon Lambda-1a, in Combination with Ribavirin and Daclatasvir for Treatment of Chronic HCV Infection with Treatment Naïve Genotypes 1, 2, 3 or 4 in Subjects Coinfected with HIV-1 |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 weeks in Subjects with Chronic HCV and HIV-1 Coinfection |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
A Phase 2, Open-Label Study of Daclatasvir (BMS-790052) and TMC435 in Combination With or Without Ribavirin (RBV) For Treatment-Naive Subjects or Null Responders to Prior Peginterferon Alfa (PegIFN)/RBV Therapy with Genotype 1 Chronic Hepatitis C |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
ASN100-201: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Single Dose of ASN100 for the Prevention of Staphylococcus aureus Pneumonia in Heavily Colonized, Mechanically Ventilated Subjects |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Cepheid 077B-C: Evaluation of the Xpert® MTB/RIF Assay |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of GS-7977 plus Ribavirin for 12 Weeks in Chronic Genotype 2 and 3 Hepatitis C Virus (HCV) Coinfected Subjects (GS-US-334-0123) |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
GS-US-380-4030: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed Dose Co |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
M14-730 (EXPEDITION-2): A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Human Immunodeficiency Virus-1 (HIV-1) Co-Infection |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
ACTG A5295: Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in HIV-Infected and HIV-Uninfected Pulmonary Tuberculosis Suspects |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
MK-3682B-037-00A: Phase 3 Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B (Grazoprevir/Ruzasvir/Uprifosbuvir) in Participants with Chronic Hepatitis C Virus Genotype 3 Infection |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
DAIDS A5298 Study: A Randomized, Double-Blinded, Placebo-Controlled, Phase III Trial of the Quadrivalent HPV Vaccine to Prevent Anal Human Papillomavirus Infection in HIV-Infected Men |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Cardiovascular, Anthropometric, and Skeletal Effects of ART Initiation with FTC/TDF plus ATV/r: Metabolic Substudy (ACTG) A5260s |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of a Novel CCR5 Antagonist, UK427,857, for the Treatment of Antiretroviral-Experienced HIV-1-Infected Subjects |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naive Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who are on Opiate Substitution Therapy |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Pfizer A4001027: Observational Phase Extension |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
GSK_201585: Phase III, randomized, multicenter, parallel-group, non inferiority, open-label study evaluating the efficacy, safety, & tolerability of switching to long-acting cabotegravir plus long acting rilpivirine from current INI,NNRTI, or PI-based ART |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
A phase III trial to investigate the efficacy, tolerability & safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR in HIV-1 infected subjects w/ limited to no treatment options |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
ACTG A5294: A Prospective, Phase III Open-Label Study of Response-Guided Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Study of BMS-790052 plus Peg-Interferon alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected with HIV and HCV |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Entecavir Intensification for HIV-HBV Coinfected subjects with persistent HBV viremia |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Gilead GS-US-236-0102 |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 and ABT-333 Coadministered with Ribavirin in Adults with Genotype 1 Chronic HCV and HIV |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
A Probe to Evaluate the Safety, Tolerability & Immunogenicity of the MRK Adenovirus Serotype 5 Vector Human Immunodeficiency Virus Type 1 gag Vaccine in HIV-1 Infected |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
GS_US_342-1139: Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 12 Weeks in Subjects with Chronic Genotype 2 HCV Infecti |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Subjects with Chronic Hepatitis C |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Tobira 652-2-202 Pre-Clinical Trial Cost Agreement |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Subjects with Chronic Hepatitis C |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Metabolic Substudy of A5257, CIMT/FMD Repeat Scans (ACTG A5260s:) |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
ViiV Healthcare A4001098 |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
GS-US-183-0130: A Phase 3, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS-9137 (GS-9137/r) Administered in Combination with Other Antiretroviral Agents in the Treatment of HIV-1 Infected Subjects |
Anne Luetkemeyer, MD |
Division of HIV, ID and Global Medicine |
|
|
|
HIV Incidence Testing using Multiple Biological Specimens |
Christopher Pilcher, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Targeting Acute HIV |
Christopher Pilcher, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Performance Evaluation of the Bio-Rad Geenius HIV-1/2 Supplemental Assay |
Christopher Pilcher, MD |
Division of HIV, ID and Global Medicine |
|
|
|
HIV Incidence Testing in Hair |
Christopher Pilcher, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
The effects of alcohol on acute HIV associated neurocognitive disorders |
Christopher Pilcher, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Wave 80 Fingerstick Pilot Study |
Christopher Pilcher, MD |
Division of HIV, ID and Global Medicine |
|
|
|
High Throughput Measurement of Envelope Gene Diversity for an HIV Incidence Assay |
Christopher Pilcher, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
A Pilot of Intervention to Promote Acute HIV Testing by Ambulatory Care Providers |
Christopher Pilcher, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Data Collected through the IAVI Early Infection Cohort Study |
Christopher Pilcher, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
HIV RNA and/or Antibody Confirmed Positive Plasma |
Christopher Pilcher, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Development of Specimen Repository and Evaluation of Assays for Identification of Recent HIV Infection |
Christopher Pilcher, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Host Factors Influencing HIV Viral Load and Infectivity in Semen |
Christopher Pilcher, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
A Multi-Centric Evaluation of a Device for Automated Malaria Microscopy (EasyScan Go) |
Philip J. Rosenthal, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Discovery of Oxaboroles as New Antimalarial Agents |
Philip J. Rosenthal, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
The Impact of Food Insecurity on HIV Outcomes and Sexual Risk Behavior in Uganda |
Sheri Weiser, MD |
Division of HIV, ID and Global Medicine |
|
|
|
The Impact of Food Insecurity on HIV Outcomes and Sexual Risk Behavior in Uganda |
Sheri Weiser, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Changing Health through Food Support (CHeFS) Program- Expanded Program |
Sheri Weiser, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine, Prevention Science (formerly the Center for AIDS Prevention Studies or CAPS) |
|
|
|
Mechanisms and longitudinal effects of HIV-related stigma on women's adherence and outcomes |
Sheri Weiser, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Changing Health through Food Support (CHeFS) Pilot Study (POH) |
Sheri Weiser, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Pathways from Food Insecurity to Health and Treatment Outcomes in Women with HIV |
Sheri Weiser, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Exploring the Impact of Urban Gardens on Food Insecurity and Health of Low Income Californians: A Community Research Partnership |
Sheri Weiser, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Multi-Sectoral Agricultural Intervention to Improve Nutrition, Health and Developmental Outcomes of HIV-infected and Affected Children in Western Kenya |
Sheri Weiser, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Assessing the preliminary effects of a multisectoral agricultural intervention on the sexual and reproductive health of HIV-affected adolescent girls |
Sheri Weiser, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Mentoring in Patient Oriented Research on Food Insecurity, HIV and Aging, Weiser K24 |
Sheri Weiser, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Pathways from Food Insecurity to Health and Treatment Outcomes in Women with HIV, WEISER CONTINUTATION |
Sheri Weiser, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Pathways contributing to racial disparities among HIV clinic cohort patients |
Sheri Weiser, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine, Prevention Science (formerly the Center for AIDS Prevention Studies or CAPS) |
|
|
|
Women's Interagency HIV (WIHS-V) S. Weiser |
Sheri Weiser, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Exploring the Bidirectional Relationship between Food Security and HIV Treatment Outcomes in a Rural Ugandan Cohort |
Sheri Weiser, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Food Insecurity: A Key Structural Barrier to HIV/AIDS Care |
Sheri Weiser, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Gender Effects on HIV Biology |
Ruth Greenblatt, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Women's Specialty Program Infrastructure Support Contract |
Ruth Greenblatt, MD |
Division of HIV, ID and Global Medicine |
|
|
|
WIHS Treatment Exposure and Viral Rebound Study / AIDS Research |
Ruth Greenblatt, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Chicago Women's Interagency HIV Study Consortium (WIHS) Biostatistical Data Analyses |
Ruth Greenblatt, MD |
Division of HIV, ID and Global Medicine, Department of Clinical Pharmacy, AIDS Research Institute |
|
|
|
Chronic Care HIV/AIDS Multidisciplinary Program (CCHAMP) Center of Excellence |
|
Division of HIV, ID and Global Medicine |
|
|
|
KAM Training |
|
Division of HIV, ID and Global Medicine |
|
|
|
Family Service Networks - Centers of Excellence |
|
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Family Services Network - Ryan White HIV/AIDS Program |
|
Division of HIV, ID and Global Medicine |
|
|
|
HIV Health Services - Program Database Services |
|
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Chronic Care HIV/AIDS Multi-Disciplinary Program (CCHAMP) |
|
Division of HIV, ID and Global Medicine |
|
|
|
Darpun Sachdev mentored participation in HIV Clinical Trials |
|
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Sexual Harm Reduction for HIV+ Gay Men (Prevention with Positives) |
|
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Outpatient Services Ward 86 |
|
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
HIV Treatment Training for Clinical Setting |
|
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Ryan White Title IV Program: Integrated Family Services Network / AIDS-related |
|
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Ryan White Title IV Program: Family Services Network |
|
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Hepatitis C Co-infection Clinic: A to T (Acute to Transplant) |
|
Division of HIV, ID and Global Medicine |
|
|
|
Positive Health Access to Service and Treatment (PHAST) |
|
Division of HIV, ID and Global Medicine |
|
|
|
Abbott Preceptorship |
|
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Primary Care Services- Non Severe Need - Ward 86 |
|
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Stored Blood Specimens |
|
Division of HIV, ID and Global Medicine |
|
|
|
Treatment of Acute Hepatitis C Virus in HIV Co-Infection |
|
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Ward 86 Outpatient Services/Perinatal Services |
|
Division of HIV, ID and Global Medicine |
|
|
|
African American Center of Excellence |
|
Division of HIV, ID and Global Medicine |
|
|
|
Ward 86 Outpatient Services/Perinatal Services |
|
Division of HIV, ID and Global Medicine |
|
|
|
Expanded HIV Testing for Disproportionately Affected Population |
|
Division of HIV, ID and Global Medicine |
|
|
|
She's Living Positive Health Fair |
|
Division of HIV, ID and Global Medicine |
|
|
|
Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Who Have Chronic HCV-1/HIV-1 Co-Infection and Are Treatment-Naïve for Hepatitis C |
|
Division of HIV, ID and Global Medicine |
|
|
|
CHRP for Integrating HIV and Geriatric for People Living with HIV 50 and Over |
|
Division of HIV, ID and Global Medicine |
|
|
|
Positive Health Access to Services and Treatment (PHAST) |
|
Division of HIV, ID and Global Medicine |
|
|
|
VX11-950-115 An Open Label, Phase 3 Study of Telaprevir in Combination With Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Coinfected With Genotype 1 Hepatitis C Virus and Human Immunodeficiency Virus Type 1(HCV/HIV-1) |
|
Division of HIV, ID and Global Medicine |
|
|
|
The Use of Nelfinavir During Acute or Early HIV Infection - Safety, Tolerability, Durablilty and Resistance |
|
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Women's Center of Excellence |
|
Division of HIV, ID and Global Medicine |
|
|
|
Ward 86 Outpatient Services / Perinatal Services |
|
Division of HIV, ID and Global Medicine |
|
|
|
Chronic Care HIV/AIDS Multidisciplinary Program (CCHAMP) |
|
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Positive Health Access to Service and Treatment (PHAST) |
|
Division of HIV, ID and Global Medicine |
|
|
|
Positive Health Access to Services and Treatment (PHAST) |
|
Division of HIV, ID and Global Medicine |
|
|
|
Informing interventions to reduce tobacco use among homeless women |
Elise Riley, PhD |
Division of HIV, ID and Global Medicine |
|
|
|
Mentoring patient-oriented research on the health consequences of polydrug use |
Elise Riley, PhD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
HPV Epidemiology and Response to Screening (HEARTS) |
Elise Riley, PhD |
Division of HIV, ID and Global Medicine |
|
|
|
Effects of Polydrug Use, Adulterants and HIV on Cardiac Injury in Homeless Women |
Elise Riley, PhD |
Division of HIV, ID and Global Medicine |
|
|
|
Effects of Housing and HIV on Risk Behavior and Victimization of Indigent Women |
Elise Riley, PhD |
Division of HIV, ID and Global Medicine |
|
|
|
Updating HCV treatment engagement paradigms for HIV/HCV coinfected patients |
Elise Riley, PhD |
Division of HIV, ID and Global Medicine |
|
|
|
The Influence of Pharmacy-Based Syringe Disposal on Unsafe Syringe Discard Among Injection Drug Users in California |
Elise Riley, PhD |
Division of HIV, ID and Global Medicine |
|
|
|
Seek, Test, Treat and Retain Strategies Leveraging Mobile Health and Internet-Based Technologies |
Jacqueline Tulsky, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Administering Buprenorphine in the San Francisco County Jail |
Jacqueline Tulsky, MD |
Division of HIV, ID and Global Medicine |
|
|
|
A Clinical Trial of DOT for HAART in Jailed Drug Users / AIDS Related |
Jacqueline Tulsky, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Crossing Boundaries: Continuity of Medical Care for Incarcerated Adults |
Jacqueline Tulsky, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Short-term and long-term effects of methamphetamine exposure on residual viral transcription during treated HIV disease |
Sulggi Lee, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Host genetic predictors of plasma IL-1b levels and pharmacogenomics of in vivo IL-1b blockade during treated HIV disease |
Sulggi Lee, MD |
Center for AIDS Research (CFAR), Division of HIV, ID and Global Medicine |
|
|
|
A Pharmacogenomics Study of HIV Latency: The Role of Anti-Programmed Cell Death-1 (PD-1) Signaling |
Sulggi Lee, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Host Genetic Predictors of IDO-induced Tryptophan Catabolism Among HIV-Infected Ugandans Maintaining Treatment-Mediated Viral Suppression |
Sulggi Lee, MD |
Center for AIDS Research (CFAR), Division of HIV, ID and Global Medicine |
|
|
|
A Phase III Multicenter Randomized Study of the Biological and Clinical Efficacy of Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients with Low CD4+ Counts (SILCAAT) |
James Kahn, MD, MPH |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Behavioral, Basic, and Clinical Studies of PEP |
|
Division of HIV, ID and Global Medicine |
|
|
|
The Social Context of HIV Post-Exposure Prophylaxis (PEP) |
|
Division of HIV, ID and Global Medicine |
|
|
|
Award - Development of a Social Network-enhanced Adherence Intervention for PrEP in Young African Women |
Catherine Koss, MD |
Division of HIV, ID and Global Medicine |
|
|
|
Understanding HIV Pre-exposure Prophylaxis Engagement among Women in East Africa |
Catherine Koss, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Office of the UN Special Envoy for Tuberculosis |
Eric Goosby, MD |
Institute for Global Health Sciences (IGHS), Division of HIV, ID and Global Medicine |
|
|
|
UN Special Envoy for Tuberculosis: Strategic Priorities |
Eric Goosby, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Reactivation of latent HIV using recombinant galectin-9 |
|
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Childhood Tuberculosis Infection Among School-Age Children in Rural Uganda |
Carina Marquez, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Childhood Tuberculosis Infection Among School-Age Children in Rural Uganda |
Carina Marquez, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Capacity Based Assistance (CBA) for High Impact HIV Prevention to Health Departments in the United States |
|
Division of HIV, ID and Global Medicine |
|
|
|
Continuum of HIV Prevention Care Services |
|
Division of HIV, ID and Global Medicine |
|
|
|
The Women's HIV Program at UCSF & Rhodessa Jones |
Edward Machtinger, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Health, Empowerment, and Recovery Services (HERS) Program |
Edward Machtinger, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Targeted Treatment of Early Cryptococcal Infection in HIV-infected Patients |
|
Division of HIV, ID and Global Medicine |
|
|
|
Identifying barriers to diabetes and HIV co-management in vulnerable populations |
Kartika Palar, PhD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Impact of a novel multicomponent nutrition intervention on cardiovascular disease risk factors among food-insecure adults with HIV in the Dominican Republic |
Kartika Palar, PhD |
Division of HIV, ID and Global Medicine |
|
|
|
Improving care delivery for people living with HIV, TB and other chronic diseases through diplomacy |
Michael J. Reid, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Vulnerable youth, homelessness, and risk behaviors |
Colette L. Auerswald, MD, MS |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
UCSF- Kenyan radiology residency training |
William Dillon, MD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine, Department of Radiology and Biomedical Imaging |
|
|
|
The impact of antimalarials and insecticide resistance on malaria transmission in Uganda |
Melissa Conrad, PhD |
Division of HIV, ID and Global Medicine |
|
|
|
The impact of antimalarials and insecticide resistance on malaria transmission in Uganda |
Melissa Conrad, PhD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Antimalarial drugs in Ugandan populations |
Melissa Conrad, PhD |
Division of HIV, ID and Global Medicine |
|
|
|
The impact of antimalarial resistance on malaria transmission in Uganda |
Melissa Conrad, PhD |
Division of HIV, ID and Global Medicine |
|
|
|
Engagement in Clinical Care for HIV-Infected Individuals Leaving Jail |
Kim Koester, PhD |
Division of HIV, ID and Global Medicine |
|
|
|
Reducing dietary risks associated with noncommunicable disease |
|
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Integrated Community-based Treatment of HIV and Hypertension in Zambia |
Monika Roy, MD |
Division of HIV, ID and Global Medicine, AIDS Research Institute |
|
|
|
Measuring and Understanding the Impact of Patient Race and Ethnicity on Physician Care in Illinois |
Janette Tang, MS |
IGHS: Global Health Education, Division of HIV, ID and Global Medicine |
|
|
|
Estimating the burden of arboviruses in Uganda using age-stratified serological data |
Isabel Rodriguez Barraquer, MD, PhD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Epidemiology of vector borne diseases |
Isabel Rodriguez Barraquer, MD, PhD |
IGHS Faculty Affiliate, Division of HIV, ID and Global Medicine |
|
|
|
Leveraging Social Networks to Improve Retention in Care and Viral Suppression Among HIV-infected Youth in East Africa |
Lillian B. Brown, MD, PhD |
Division of HIV, ID and Global Medicine |
|
|
|
UnMASC: Uganda Malaria Actionable Surveillance in the time of Coronavirus |
Melawit Tekeste, MS |
Division of HIV, ID and Global Medicine |
|
|